MedPath

DAS-MG, Inc

Ownership
Private
Employees
-
Market Cap
-
Website

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

Phase 2
Recruiting
Conditions
Myasthenia Gravis
Interventions
First Posted Date
2020-01-13
Last Posted Date
2024-07-12
Lead Sponsor
DAS-MG, Inc
Target Recruit Count
24
Registration Number
NCT04226170
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath